Loading
A phase 3 trial of Pimicotinib(ABSK021) in tenosynovial giant cell tumour, run by Abbisko Therapeutics Co, Ltd, active and no longer recruiting.
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) is a phase 3 interventional study registered as NCT05804045 by Abbisko Therapeutics Co, Ltd, with 94 participants enrolled, started 2023-04-27 and due to reach its primary completion in 2024-09-23. Interventions recorded: Pimicotinib(ABSK021) and Placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
94 enrolled.
95% CI 40.9 to 66.6; Figures from the ClinicalTrials.gov results section (first posted 2026-05-04), not from a publication · 95% CI 0.1 to 16.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR)primary | Part 1- Pimicotinib(ABSK021) | 63 | 54% | - | <0.0001 | link |
| Part 1- Placebo | 31 | 3.2% |
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics, Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.